醋酸奥曲肽与艾司奥美拉唑钠配伍治疗急性胰腺炎效果分析

The Effect of Combination Therapy of Octreotide Acetate and Esomeprazole Sodium on Inflammation and Prognosis Recovery in Patients with Acute Pancreatitis

目的研讨醋酸奥曲肽与艾司奥美拉唑钠两药共治对急性胰腺炎(Acute pancreatitis,AP)患者机体炎症反应及预后恢复的影响。方法选取2020年10月至2023年8月福建中医药大学附属福州中医院收治的AP患者86例,结合随机数表法设计研究组别,对照组与观察组各43例。对照组予以醋酸奥曲肽用药,观察组予以醋酸奥曲肽联合艾司奥美拉唑钠方案用药,对比两组方案疗效。结果治疗后,观察组方案疗效高于对照组(χ^(2)=4.073,P<0.05)。两组患者急性生理学及慢性健康状况评分系统Ⅱ(Acute physiology and chronic health scoring systemⅡ,APACHEⅡ)得分均明显下降(t=71.274,P<0.05;t=43.718,P<0.05),且观察组APACHEⅡ得分较对照组明显下降(t=12.030,P<0.05)。观察组3项机体炎症指标[白细胞介素-2(Interleukin-2,IL-2)、白细胞介素-6(Interleukin-6,IL-6)与白细胞计数检测值均低于对照组(t值分别为3.740、5.188、4.352,P值均<0.05)。观察组预后恢复相关指标(自主排便、腹痛缓解、腹胀改善及住院)时间均短于对照组(t值分别为3.183、2.561、2.216、2.058,P值均<0.05)。结论对AP患者实施醋酸奥曲肽及艾司奥美拉唑钠两药共治效果明显,可更有效减轻机体炎症反应,改善患者的健康状况,促进其预后恢复。

Objective To investigate the effects of the combination of octreotide acetate and esomeprazole sodium on the inflammatory response and prognosis recovery in patients with acute pancreatitis(AP).Methods 86 AP patients admitted to Fuzhou Traditional Chinese Medicine Hospital affiliated with Fujian University of Chinese Medicine from October 2020 to August 2023 were selected.They were divided into the observation group and the control group,with 43 patients in each group.The control group was treated with octreotide acetate,while the observation group was treated with octreotide acetate combined with esomeprazole sodium regimen.The therapeutic effects of the two groups were compared.Results After treatment,the therapeutic effect of the observation group was higher than that of the control group(χ^(2)=4.073,P<0.05).The acute physiology and chronic health scoring system II(APACHE II)scores of both groups of patients decreased significantly(t=71.274,P<0.05;t=43.718,P<0.05),and the APACHE II scores of the observation group decreased more significantly compared to the control group(t=12.030,P<0.05).The observation group had three inflammatory indicators of the body,and the values of interleukin-2(IL-2),interleukin-6(IL-6),and white blood cell count were lower than those of the control group(t-values of 3.740,5.188,and 4.352,respectively,with P values<0.05).The observation group had shorter recovery time for prognostic indicators(spontaneous defecation,relief of abdominal pain,improvement of abdominal distension,and hospitalization)compared to the control group(t-values of 3.183,2.561,2.216,and 2.058,respectively,with P values<0.05).Conclusion The combination of octreotide acetate and esomeprazole sodium has a significant therapeutic effect on AP patients,which can effectively reduce the body's inflammatory response,improve the patient's health status,and promote their prognosis recovery.